Humalog ® (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Humalog Summary of Product Characteristics (SmPC)

Humalog® (insulin lispro): Changing from other mealtime insulin products

Dose adjustment may be needed when transitioning from another insulin to insulin lispro.

Detailed Information

Dose adjustment may be needed when transitioning from another insulin to IL-100.1

A change in dosage of insulin may be needed when there are changes in

  • strength

  • brand (manufacturer)

  • type (regular/soluble, NPH/isophane, etc)

  • species (animal, human, human insulin analogue) and/or

  • method of manufacture (recombinant DNA versus animal-source insulin).2

For fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across the whole day, particularly nocturnal/fasting glucose control.2

Transferring a patient with DM to another type or brand of insulin should be done under strict medical supervision.2

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Humalog [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

DM = diabetes mellitus

GC = glucose control

IL-100 = Humalog® (insulin lispro) 100 units/mL

Date of Last Review: January 27, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question